Floatz logo

Thiotepa

Myeloid Leukemia in Relapse (Disorder)

Dana-Farber Cancer InstituteSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Myeloid Leukemia in Relapse (Disorder) cohort.

Asset / SponsorPhaseRating
Fludarabine
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Actinium Pharmaceuticals
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
juvenile myelomonocytic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →